Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mepivacaine + fentanyl is a combination of two pharmaceutical agents used primarily in anesthesia and analgesia. Mepivacaine is an amide-type local anesthetic with intermediate duration, commonly used for local or regional anesthesia by infiltration, nerve block, or epidural routes. It works by blocking sodium channels on neuronal membranes, thereby inhibiting nerve impulse conduction and producing loss of sensation[1][3]. Fentanyl is a potent synthetic opioid agonist at the mu-opioid receptor, providing strong analgesic effects and often used as an adjunct to local anesthetics in various forms of anesthesia[4][5][6]. When combined (e.g., intrathecally), mepivacaine provides rapid-onset sensory and motor block while fentanyl enhances the quality and duration of analgesia without significantly affecting neonatal outcomes in obstetric settings[2]. This combination may be chosen for procedures requiring both effective regional anesthesia and enhanced pain control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mepivacaine + fentanyl.